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Background: Previous research has shown that diet can modify the bronchoconstrictor
response to exercise in asthmatic subjects.
Objective: Determine the effect of ascorbic acid supplementation on pulmonary function
and several urinary markers of airway inflammation in asthmatic subjects with exercise-
induced bronchoconstriction (EIB).
Methods: Eight asthmatic subjects with documented EIB participated in a randomized,
placebo controlled double-blind crossover trial. Subjects entered the study on their usual
diet and were placed on either 2 weeks of ascorbic acid supplementation (1500mg/day) or
placebo, followed by a 1-week washout period, before crossing over to the alternative
diet. Pre- and post-exercise pulmonary function, asthma symptom scores, fraction of
exhaled nitric oxide (FENO), and urinary leukotriene (LT) C4–E4 and 9a, 11b-prostagladin
(PG)F2] were assessed at the beginning of the trial (usual diet) and at the end of each
treatment period.
Results: The ascorbic acid diet significantly reduced (po0.05) the maximum fall in post-
exercise FEV1 (6.472.4%) compared to usual (14.371.6%) and placebo diet
(12.972.4%). Asthma symptoms scores significantly improved (po0.05) on the ascorbic
acid diet compared to the placebo and usual diet. Post-exercise FENO, LTC4–E4 and 9a,
11b-PGF2 concentration was significantly lower (po0.05) on the ascorbic acid diet
compared to the placebo and usual diet.Elsevier Ltd. All rights reserved.
s funded, in part, by the Gatorade Sports Science Institute.
855 0753; fax: +1 812 855 3193.
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induced airway narrowing in asthmatic subjects.
& 2007 Elsevier Ltd. All rights reserved.Table 1 Pre-exercise (baseline) pulmonary function.
Diet
Usual Ascorbic
acid
Placebo
FVC (l) 4.3970.42 4.2970.52 4.3470.48
% Predicted 90.076.8 87.278.9 88.577.9
FEV1 (l) 3.8270.37 3.6570.38 3.7770.37
% Predicted 97.076.1 92.277.0 95.577.0
FEF25–75%
(l/min)
4.270.36 4.170.37 4.270.42
% Predicted 100.478.7 98.878.7 100.6711.7
FEV1/FVC 87.173.2 87.173.9 87.972.6
% Predicted 79.171.2 79.174.2 79.476.2
Definition of abbreviations: FVC, forced vital capacity; FEV1,
forced expiratory volume in 1-s; FEF25–75%, forced expiratory
flow at 25–75% of FVC.
Values are mean7SD. There were no significant difference
(p40.05) for any variables between diets.Introduction
Exercise is a powerful trigger of asthma symptoms, and
up to 90% of asthmatics experience exercise-induced
bronchoconstriction (EIB) a condition in which there is a
transient narrowing of the airways during and/or following
exercise.1 EIB is not an isolated disorder or specific disease,
but rather part of the spectrum of asthmatic disease where
exercise is one of many stimuli that may induce airflow
limitation.2
The trigger for EIB most likely involves drying and cooling
of the intrathoracic airway as the result of an increased
ventilatory demand during exercise.2 It has been suggested
that dry air hyperpnea initiates a transient dehydration,
which causes an increase in the osmolarity of the airway
surface fluid,3 thereby activating epithelial cells, histamine
and proinflammatory eicosanoids (prostaglandins and leuko-
trienes) and subsequent bronchoconstriction.4 It has also
been suggested that rapid rewarming of the airways
following exercise may lead to vascular hyperemia and
airway edema,5 which may contribute further to the airway
narrowing.
At present the treatment of EIB almost exclusively
involves the use of pharmacotherapy to treat this condition.
However, there is mounting evidence that dietary modifica-
tion and/or supplementation has potential to modify the
EIB response in asthmatic individuals.6 Dietary antioxidants
and their influence on the severity of EIB are of parti-
cular interest because oxidative damage has been impli-
cated in asthma.7 Reactive oxygen species (ROS) and
reactive nitrogen species (RNS) have been shown to induce
proinflammatory cell activation, increase mucus secretion,
and increase hyperresponsiveness, all of which lead to
epithelial damage and airway inflammation.7 Thus, antiox-
idant supplementation may be instrumental in reducing EIB
severity by inhibiting this cascade of proinflammatory
events as a result of neutralizing the effects of excess
ROS/RNS.
Ascorbic acid (vitamin C) is the most extensively
investigated antioxidant for effects on asthma and has been
shown in numerous case–control and cross-sectional studies
to be associated with a reduced risk of asthma.8 Interven-
tional studies investigating the role of either a single dose or
extended antioxidant supplementation on EIB have gener-
ally shown a protective effect.9–15
However, no studies to date have attempted to investi-
gate a number of biological markers of airway inflammation
associated with EIB on a diet supplemented with ascorbic
acid. Therefore, the main aim of this study was to determine
the effects of 2 weeks of ascorbic acid supplementation on
pulmonary function and several urinary markers of airway
inflammation in asthmatic subjects with EIB. We hypothe-
sized that ascorbic acid supplementation would decrease
markers of airway inflammation and reduce the broncho-
constrictor response to exercise.Methods
Subjects
Eight subjects (2 males, 6 females, age 24.574.8 yr, _VO2max
48.7710.9ml/kg/min, height 176.8713.5 cm) with physi-
cian-diagnosed asthma were recruited from a population of
university students and the local community, and all
indicated that they were recreationally active. All subjects
had clinically treated mild-to-moderate persistent asthma
with an FEV1 greater than 70% of predicted (Table 1), and
documented EIB (usual diet) as indicated by a drop of
greater than 10% in post-exercise FEV1 compared with pre-
exercise values.16
All subjects had a history of chest tightness, shortness of
breath and intermittent wheezing following exercise. As per
previous studies, subjects were asked to discontinue taking
leukotriene receptor antagonists [(LTRAs; N ¼ 3 montelu-
kast (Singulairs)] 12 h prior to testing,10,13,14 and 4 days
prior to testing to abstain from taking combined inhaled
corticosteroids (ICS) and long-acting b2-agonists [N ¼ 2,
fluticasone propionate (Flovents) and salmeterol (Advairs)]
or combined long-acting b2-agonists and LTRAs [N ¼ 3
salmeterol (Advairs) and montelukast (Singulairs)].9 In
addition, all subjects were asked to refrain from taking
caffeine, and to avoid physical activity 12 and 24 h,
respectively, before exercise testing. Subjects were asked
to abstain from taking antioxidant supplements other than
those given during the course of the study. Each subject
completed a health questionnaire and gave written in-
formed consent prior to enrollment in the study. All testing
procedures and informed consent were approved by the
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Study design and protocol
The study was conducted as double-blind, randomized,
crossover trial over 5 consecutive weeks with each subject
serving as their own control. All subjects entered the study
on their usual diet. Subsequently, they were randomly
assigned to either a pharmaceutical grade ascorbic acid
supplement [1500mg/day (3 500mg capsules), NOW
foods, Bloomingdale, IL] or a matched (color/size) placebo
[(3 capsules/day of sucrose), NOW foods, Bloomingdale, IL]
for a 2-week period. Thereafter, they followed a 1-week
washout period. Afterward, subjects were then assigned the
alternate treatment/placebo for the remaining 2 weeks.
Subjects were advised to avoid foods that were high in
Vitamin C during the study period so that any effects on
dependent variables could be attributed to the ascorbic acid
supplement.
Upon entering the study on their usual diet and following
each 2-week supplementation period, pulmonary function
was assessed pre- and post-exercise at 1, 5, 10, 15, 20, and
30min. The fraction of exhaled nitric oxide (FENO), an
indirect marker of airway inflammation, was measured pre-
exercise and at 30 and 120min post-exercise. Urine samples
were taken pre-exercise and 90min post-exercise and
analyzed for the presence of proinflammatory mediators
[cysteinyl leukotriene (LT) C4–E4 and 9a, 11b-prostaglandin
(PG)F2)]. Urine samples were stored at 80 1C until analysis.
Twenty-four hour dietary recalls were administered upon
entry into the study and during each supplementation
period. At the end of the 1-week washout period pulmonary
function was assessed pre- and post-exercise to ensure that
values had returned to baseline.
Exercise challenge testing
Each subject ran on a motorized treadmill (Quinton, Bothell,
WA) which was elevated 1% per minute until 85% of age
predicted maximum heart rate and ventilation exceeding
40–60% of predicted MVV (MVV estimated by 35 FEV1).16
Subjects maintained this exercise intensity for 6min.16
Following the 6-min steady state exercise, the grade of the
treadmill continued to increase at 1% per minute until
volitional exhaustion. Heart rate was monitored using a F1
Polar Heart Rate Monitor (Polar, Helsinki, Finland). Breath-
by-breath analysis of expired gases was accomplished by
indirect open circuit calorimetry (SensorMedics Vmax 22
metabolic cart, SensorMedics Corp., Yorba Linda, CA).
Pulmonary function
Spirometry was performed in all subjects using a computer-
ized pneumotachograph spirometer (SensorMedics Vmax 22,
SensorMedics Corp., Yorba Linda, CA) according to American
Thoracic Society recommendations.17 The maximum per-
centage fall in FEV1 from the baseline (pre-exercise) value
was calculated using the following equation: (pre-exercise
FEV1lowest post-exercise FEV1)/(pre-exercise FEV1). In
addition, bronchoconstriction was assessed using area underthe curve of the percentage fall in post-exercise FEV1
plotted versus time for 30min (AUC0–30). The AUC030 was
computed using trapezoidal integration.
Fraction of exhaled nitric oxide
Fraction of exhaled nitric oxide (FENO) was measured with
an online measurement of resting values using a restricted
exhaled breath protocol (NOA 280i Nitric Oxide Analyzer,
Accurate NO Breath Kit, Thermal Mass Flowmeter, NO
Analysis software Version 3.21, Sievers Instruments, Boulder,
CO). Measurements were conducted as outlined by American
Thoracic Society guidelines.18 Three exhalations were
performed with nose clips at each test with at least 30 s
between exhalations. The procedure entailed maximal
inhalation to total lung capacity and immediate exhalation
against expiratory resistance for at least 6 s to obtain a NO
plateau lasting at least 3 s. Subjects were instructed to
maintain a flow rate of 50710ml/s as monitored by a
computer display.
Asthma symptom questionnaire
In order to document asthma symptoms during the course of
the study, subjects were required to complete the symptoms
section (12 items) of the self-administered Asthma Quality
of Life Questionnaire (AQLQ) at the beginning of the study
and at the end of each treatment period. The symptoms
section of the questionnaire asks subjects to rank the
severity of their symptoms over each 2-week treatment
period, and to respond to each question on a 7-point interval
scale (e.g., 1 ¼ a very great deal of discomfort or distress to
7 ¼ no discomfort or distress). Results are analyzed directly
from the scores recorded on the questionnaire, with the
overall score being expressed as a mean of all the items. The
minimum important difference, for both quality of life and
individual domains, has been calculated as a change of 0.5
per item; a change of 1.0 is considered moderate and a
change of 1.5 is considered large.19
Urinary 9a, 11b PGF2 and LTC4–E4 quantification
The urinary concentrations of inflammatory mediators
(LTC4–E4 and 9a, 11b-PGF2) were determined by enzyme-
linked immunoassay (Neogen, Lexington, KY). The plates
were washed using an EL 405 Automated Plate Washer
(Bio-Tek Instruments, Winooski, VT) and read at 650 nm
using a Powerwave XS Spectrophotometer (Bio-Tek Instru-
ments, Winooski, VT). Inter-assay and intra-assay coeffi-
cients of variation for both eicosanoid kits were o10%.
Inflammatory mediator concentration was adjusted for
creatinine concentration (Cayman Chemicals, Ann Arbor,
MI). The intra-assay and inter-assay coefficient of variation
for creatinine was 2.7% and 3%, respectively.
Dietary analysis and compliance
Dietary intake was assessed for three 24-h periods during the
study for each subject. Twenty four hour dietary recalls
were collected by a registered dietitian in a personal
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System for research software (University of Minnesota,
School of Public Health, St. Paul, MN). All subjects
participated in one interview at the beginning of the study
to reflect their usual dietary intake. The second and third
interviews occurred during the ascorbic acid supplementa-
tion and placebo periods. These recalls were conducted to
see if the subjects were indeed complying with the
restriction instructions and that diet patterns were similar
over the study period. Adherence to the supplementation
regimen was assessed by asking the subjects to document
the dose of capsules consumed daily. In addition, subjects
were asked to return any unused capsules, another indicator
of adherence.
Statistical analysis
Data were analyzed using SPSS version 13.0 statistical
software. A repeated-measures ANOVA was used to analyze
the data with both treatment and time as the ‘‘within-
subject’’ effects. A Mauchly’s test was conducted to
determine if sphericity was violated. In cases where
sphericity was violated, a Gieser-Greenhouse correction
was applied. Where a significant F-ratio was found
(po0.05), Fisher’s protected least-square difference post
hoc test was used to isolate differences in group means
(po0.05). Diet recalls were compared between study
periods using 2 2 repeated-measures ANOVA. Dietary
vitamin intake such as ascorbic acid and other antioxidant
nutrients, as well as macronutrient intake, were compared.
A pairwise t-test was used to assess differences in symptom
scores between diets. Data were analyzed for the presence
of carryover effects between treatments using a 2 2
ANOVA. Statistical significance was set at po0.05. Data
are expressed as mean and their 95% confidence intervals
(95% CI). Effect size (ES) estimates were calculated using
omega-squared.20 With eight asthmatic EIB patients, the
data had at least 80% power to detect statistical signifi-
cance. Our power calculation was based on upon the work of
Neuman et al.13,14 who demonstrated an ES of 0.38 and 0.50
, for a study power of 0.97 and 0.98, respectively.
Results
The intake of dietary ascorbic acid in the subjects’ usual
diets ranged from 1.4 to 230.6mg (mean; 133.6mg), but the
ascorbic acid intake during the supplementation and
placebo periods ranged from 16.4 to 86.8mg (mean;
49.4mg), and from 3.41 to 170.29mg (mean; 49.9mg),
respectively. The lower dietary ascorbic acid intake during
supplementation period indicated compliance to the re-
striction instruction. The 2 2 repeated measure ANOVA
also indicated no significant difference (p40.05) in dietary
ascorbic acid intake between supplementation and placebo
groups. Intake of carbohydrates, protein, and fat were
similar among periods, suggesting diet patterns were
consistent. Also, intake of antioxidants did not differ, thus,
dietary intake did not confound supplementation effects.
A 2 2 ANOVA used to test for the presence of carryover
effects between diets indicated that none were present for
all dependent variables; this was further supported by pre-and post-exercise pulmonary function values at the end of
the washout period returning to baseline values established
upon entry into the study (usual diet). The absence of a
significant difference (p40.05) in minute ventilation ð _VEÞ
between any of the treatment periods suggests that
differences in dependent variables between treatments
were not due to changes in _VE but rather due to changes in
diet.
No significant difference (p40.05) was observed in
baseline (pre-exercise) pulmonary function between diets
(Table 1). The maximum percentage drop in FEV1 post-
exercise on the ascorbic acid diet was 6.4% (95% CI, 12.0
to 0.8%; ES, 0.40) which is indicative of an attenuated EIB
response. This was significantly different (po0.05) from the
maximum drop of 12.9% (95% CI, 18.6 to 12.3%) and
14.3% (95% CI, 18.1 to 10.5%) on the placebo and usual
diet (Fig. 1). The post-exercise bronchoconstrictor response,
as determined by the AUC0–30, was significantly less
(po0.05) on the ascorbic acid diet (72.5; 95% CI, 214.5
to 69.4; ES, 0.36) compared to the placebo (255.8; 95% CI,
385.2 to 126.3) or usual diet (220.9; 95% CI, 306.2 to
135.7).
A significant difference (po0.05) was observed for post-
exercise FENO on the ascorbic acid diet compared to usual
and placebo diet. Mean FENO for the ascorbic acid diet was
25.0 ppb (95% CI, 7.3–40.3 ppb) at 30 and 22.6 ppb (95% CI,
8.1–42.3) at 120min post-exercise as compared to 38.3 ppb
(95% CI, 17.5–50.7 ppb) at 30 and 38.0 ppb (95% CI,
15.3–51.7) at 120min post-exercise for the placebo diet,
and 42.5 ppb (95% CI, 13.8–83.0 ppb) at 30 and 47.1 ppb (95%
CI, 15.8–85.3) at 120min post-exercise for the usual diet.
Post-exercise FENO was not significantly different (p40.05)
between the placebo and usual diet (Fig. 2).
A significant improvement (po0.05) in mean asthma
symptom scores was observed (6.3; 95% CI, 5.8–6.8) on the
ascorbic acid diet compared to the placebo diet (5.8; 95% CI,
5.1–6.2) and usual diet (5.6; 95% CI, 5.0–6.3). However, no
significant difference (p40.05) was observed in mean
asthma symptoms scores between the usual and placebo
diet.
Mean urinary 9a, 11b PGF2 and cyst-LTC4–E4 levels are
shown in Figs. 3 and 4, respectively. Pre-exercise urinary 9a,
11b PGF2 and cyst-LTC4–E4 concentrations were not sig-
nificantly different (p40.05) between diets. However, the
urinary concentration of post-exercise 9a, 11b PGF2 was
significantly less (po0.05) on the ascorbic acid diet (5.2 ng
mmol creatinine1; 95% CI, 4.1–6.6 ngmmol creatinine1)
compared to the placebo (9.9 ngmmol creatinine1; 95%
CI, 6.2–15.3 ngmmol creatinine1) and usual diet (13.8 ng
mmol creatinine1; 95% CI, 4.7–18.7 ngmmol creatinine1)
(Fig. 3). The post-exercise urinary concentration of LTC4–E4
on the ascorbic acid diet was 5.8 ngmmol creatinine (95% CI,
1.1–9.4 ngmmol creatinine), which was significantly lower
(po0.05) than the placebo (14.3 ngmmol creatinine; 95% CI,
5.4–16.4 ngmmol creatinine) and usual diet (17.1 ngmmol -
creatinine; 95% CI, 6.5–19.3) (Fig. 4).Discussion
This double-blind, randomized, crossover, placebo-con-
trolled study has demonstrated that 1500mg/d of ascorbic
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Figure 1 The percent change in FEV1 from pre- to post-exercise across the three diets. Reductions in post-exercise FEV1 in excess of
10% represent a positive diagnosis of exercise-induced bronchoconstriction. *Ascorbic acid diet significantly different (po0.05) from
usual and placebo diet. No significant difference (p40.05) was observed for percent change in FEV1 pre- to post-exercise between
usual and placebo diet.
S.L. Tecklenburg et al.1774supplementation for 2 weeks attenuates the bronchocon-
strictive response to exercise in asthmatic subjects. The
ascorbic acid supplemented diet significantly improved post-
exercise pulmonary function as demonstrated by thereduction in post-exercise FEV1, and reduced the severity
of EIB as measured by AUC0–30. The maximum post-exercise
fall in FEV1 was approximately halved on ascorbic acid
supplemented diet compared to the usual and placebo diet.
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nificantly reduced on the ascorbic acid diet compared to the
usual and placebo diet.
The maximum decrease in FEV1 post-exercise was 14.3%
and 12.9% on the usual and placebo diets, respectively. It
is possible that these modest reductions in post-exercise
FEV1 are related to the continuation of pharmacotherapy
between tests. Even though usual medications were with-
held prior to testing, as per previous studies,9,10,13,14 it is
feasible that taking these medications between tests
may have had a protective effect against more severebronchoconstriction developing following exercise. None-
theless, we believe that the reduction in severity of
EIB found in the subjects following the ascorbic acid-
supplemented diet is of clinical significance, since the
ascorbic acid diet reduced the maximum post-exercise fall
in FEV1 by about 56% (ES, 0.40), and reduced post-exercise
FENO, cyst-LTC4–E4 and 9a, 11b PGF2 concentrations by
approximately 47%, 66% and 62%, respectively, compared to
the usual diet.
The present study is the first to measure markers of
airway inflammation on ascorbic acid supplementation in
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significant suppression of the proinflammatory urinary
eicosanoids, LTC4–E4 and PGD2 metabolite 9a, 11b PGF2.
Measurement of inflammatory mediators in urine has been
used extensively in clinical and investigative monitoring of
asthmatic patients, and previous studies have indicated that
urinary concentrations of LTE4 and 9a, 11b PGF2 increase
after exercise in adults with asthma21–23 and elite athletes
with EIB.24 9a, 11b-PGF2, the initial urinary metabolite of
prostaglandin D2, is a sensitive marker of mast cell
activation in the airways, and a potent bronchoconstrictor.23
Metabolism of inhaled doses of bronchoconstrictive media-
tors LTC4 and LTE4 in asthmatic patients strongly supports
the use of urinary cysteinyl-LTs as an index specifically
reflecting cysteinyl-LT release in airways of patients with
asthma.25 Cysteinyl-LTs are important in the pathogenesis of
EIB since they have been shown to increase following
exercise in asthmatic subjects,26 and to directly increase
eosinophilic airway inflammation and cause bronchial
smooth muscle contraction.27
Previous studies have shown that FENO can be used as an
indirect marker of asthmatic airway inflammation and can
be correlated to asthma severity, airway hyperresponsive-
ness28 and severity of EIB.29 Exhaled NO, which is derived
from NO synthase (NOS), can be detrimental because
peroxynitrite, a major metabolite of NO, causes airway
epithelial damage and airway hyperresponsivess,30 or con-
versely, is bronchoprotective in asthma through a direct
action on bronchial smooth muscle.31 The increased levels of
FENO observed in asthmatic compared to nonasthmatic
individuals is thought to be secondary to increased airway
expression of inducible NO (iNOS), which can be found in a
number of cells within the respiratory epithelium such as
monocytes and macrophages, and can be stimulated by
endogenous cytokines.32 In the present study baseline and
post-exercise FENO was significantly reduced on the ascorbic
acid diet, suggesting an amelioration of airway inflamma-
tion. Mohsenin et al.33 have demonstrated a protective
effect of oral ascorbic acid (500mg qd) on NO2-induced
airway hyperresponsiveness in humans, suggesting that oral
doses of ascorbic acid supplementation are capable of
reaching the respiratory tract.
In pulmonary diseases such as asthma, oxidant stress
induced mainly via inflammatory mechanisms inflicts tissue
injury, sensitizes cells in the lung to proinflammatory
mediators, and consequently aggravates the disease pro-
cess.34 In asthmatic subjects, cytokines released from
activated eosinophils and additional inflammatory cells can
initiate ROS/RNS generation by pulmonary macrophages,
interstitial cells and leukocytes infiltrating lung tissue.35
Excess ROS/RNS may overwhelm antioxidant defense, and
consequently lead to bronchoconstrictor mediators respon-
sible for EIB. The genes for these inflammatory mediators
are regulated by redox-sensitive transcription factors,
nuclear factor (NF)-kappa(k)B and activator protein (AP)-
1.36 NF-kB has also been shown to upregulate the gene for
iNOS resulting in increased FENO,
37 and has been implicated
in the up-regulation of pro-inflammatory cytokines, and the
release of proinflammatory eicosanoids, such as cysteinyl-
LTs and prostaglandins.37 Importantly, it has been demon-
strated that ascorbic acid blocks TNF-a-mediated activation
of NF-kB.38Prior studies indicate that there may be a link between
ascorbic acid in the diet and asthma. It has been established
that asthmatics tend to have lower serum antioxidants,
including vitamin C, and that low vitamin C intake can be
correlated with asthma severity.39,40 These data suggest
that asthmatic subjects may have an antioxidant deficiency
and/or that they have increased oxidative stress that
requires higher levels of ROS/RNS scavenging antioxidants.
Thus, it seems plausible that antioxidant supplementation
could be effective in reducing the effects of this disease.
Indeed, Fogarty et al.41 have recently shown that vitamin C
supplementation may have a modest corticosteroid sparing
effect in asthmatic patients. However, a recent Cochrane
systematic review42 evaluated the evidence for the efficacy
of vitamin C supplementation in the treatment of asthma.
The review concluded that evidence is inconclusive to
recommend a specific role for vitamin C in the treatment of
asthma.
Interventional studies using extended supplementation
periods with other antioxidants such as b-carotene, lyco-
pene, and undenatured whey protein have been effective in
improving pulmonary function in subjects with EIB.9,12–14
Neuman et al.13 found a protective effect on post-exercise
pulmonary function (post-exercise drop o15%) in EIB
subjects with a daily dose of 64mg b-carotene supplemen-
tation for 1 week. All subjects on the placebo diet
demonstrated a greater than a 15% reduction in post-
exercise FEV1. In a subsequent study, the same authors
14
found that 1 week of 30mg of lycopene (LYC-O-MATOTM)
supplementation also improved post-exercise pulmonary
function. EIB subjects demonstrated a 414% reduction in
post-exercise FEV1 (average 26.5%), while 7 days of LYC-O-
MATOTM supplementation resulted in a significant improve-
ment in post-exercise FEV1, with an average decrease in
FEV1 of 14.7%. More recently, Baumann et al.
9 found a
reduction in the severity of EIB when subjects were
supplemented with a cysteine donor whey protein for 8
weeks. Eighteen EIB-positive subjects demonstrated a
significant mean improvement in post-exercise FEV1 from
baseline (22.67+12.2%), 4 weeks (18.9712.9%) and 8
weeks (16.9711.6%), with concomitant reductions in
FEF25–75%, on the undenatured whey protein diet. No
changes in FEV1 or FEF25–75% were observed for any time
points on the placebo diet. Murphy et al.12 reported in
abstract form, that 500mg/day of ascorbic acid combined
with a-tocopherol (300mg/day) for 3 weeks improved in
post-exercise FEV1 compared to placebo.
Conversely, Falk et al.43 found that a daily dose of LYC-O-
MATOTM did not affect pulmonary function following
exercise in 19 adolescent athletes. The authors attributed
their negative findings, which contrasts with previous
research,9,12–14 to an exercise intensity which may not be
sensitive enough to document EIB in an athletic population,
a reduced environmental stress (testing took place in a
warm, humid environment) and not accounting for other
dietary factors (i.e., high dietary intake of natural anti-
oxidants such as fruits and vegetables). Interestingly,
Grievink et al.44 reported a beneficial effect of 3-month
supplementation of an ascorbic acid and tocopherol combi-
nation, with or without b-carotene, which reduced the
acute bronchoconstriction induced by ozone in healthy
cyclists following exercise.
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gated the efficacy of a single dose of ascorbic acid
supplementation on the severity of EIB. Schachter and
Schlesinger15 studied 12 asthmatics with EIB and found
significant improvement in post-exercise FEV1 with 500mg
of ascorbic acid taken 90min prior to exercise, while the
placebo treatment had no effect on post-exercise pulmon-
ary function. Cohen et al.10 studied 20 asthmatics with EIB in
which they were given either 2 g of ascorbic acid or placebo
before an exercise challenge. Nine of the 20 subjects
exhibited a protective effect on post-exercise pulmonary
function on the ascorbic acid diet. Five patients in the
protected group continued with 500mg/d ascorbic acid for 2
weeks and demonstrated continued protection. The studies
by Schachter and Schlesinger15 and Cohen et al.10 was
supported by evidence presented by Miric and Haxhiu,11 who
demonstrated that pretreatment with ascorbic acid pre-
vented a significant alteration in airway geometry induced
by exercise in asthmatic subjects.
In conclusion, this study has shown that 2 weeks of
ascorbic acid supplementation provides protection against
exercise-induced airway narrowing in asthmatic subjects.
The improvement in post-exercise pulmonary function on
the ascorbic acid diet was accompanied by significant
suppression of urinary measures of airway inflammation,
FENO and a significant reduction in the intensity of asthma
symptoms compared to the usual and placebo diet. Blocking
oxidative stress, with ascorbic acid supplementation, is
unlikely to lead to complete resolution of bronchoconstric-
tion following exercise but might be useful as an adjunct
therapy in asthma patients. Additional research should be
aimed at establishing what combination of antioxidants will
be most effective in correcting airway dysfunction, and to
assess whether dietary manipulation with natural foods,
high in antioxidants (i.e., fresh fruits and vegetables,) is as
effective as ascorbic acid supplementation in providing
protection against EIB.References
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